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In this review, we identify important challenges facing physicians responsible for renal and cardiac
transplantation in children based on a review of the contemporary medical literature. Regarding pediatric
renal transplantation, we discuss the challenge of antibody-mediated rejection, focusing on both acute and
chronic antibody-mediated rejection. We review new diagnostic approaches to antibody-mediated rejection,
such as panel-reactive antibodies, donor-specific cross-matching, antibody assays, risk assessment and diagnosis
of antibody-mediated rejection, the pathology of antibody-mediated rejection, the issue of ABO incompat-
ibility in renal transplantation, new therapies for antibody-mediated rejection, inhibiting of residual
antibodies, the suppression or depletion of B-cells, genetic approaches to treating acute antibody-mediated
rejection, and identifying future translational research directions in kidney transplantation in children.
Regarding pediatric cardiac transplantation, we discuss the mechanisms of cardiac transplant rejection,
including the role of endomyocardial biopsy in detecting graft rejection and the role of biomarkers in detecting
cardiac graft rejection, including biomarkers of inflammation, cardiomyocyte injury, or stress. We review
cardiac allograft vasculopathy. We also address the role of genetic analyses, including genome-wide association
studies, gene expression profiling using entities such as AlloMapH, and adenosine triphosphate release as a
measure of immune function using the CylexH ImmuKnowTM cell function assay. Finally, we identify future
translational research directions in heart transplantation in children.
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& INTRODUCTION
Solid-organ transplantation is an accepted treatment for
end-stage renal and cardiac diseases in children. Over the
past few decades, better methods of matching donor-
recipient pairs and newer immunosuppressive drugs have
substantially improved the overall survival of transplant
recipients. Consequently, the number of children receiv-
ing solid-organ transplants has increased tremendously.
However, improving the long-term management and quality
of life of recipients continues to be a challenge. The main
challenges are allograft rejection, the deleterious effects of the
immunosuppressive drugs, infections, malignancies, nephro-
toxicity, post-transplant lymphoproliferative disorders, and,
in some cases, recurrence of the primary disease.
The University of Miami’s Miller School of Medicine is
deeply involved in caring for a large number of children
receiving solid-organ transplants. In this article, we review
many of the challenges in caring for these children, which we
accomplish with an interdisciplinary team of pediatric
cardiologists, pediatric nephrologists, pediatric immunolo-
gists, cell biologists, molecular biologists, transplant surgeons,
pathologists, epidemiologists, and computational scientists.
We focus on antibody-mediated rejection (AMR) and the
recurrence of focal segmental glomerulosclerosis (FSGS) in
the renal section and on biomarkers for rejection and
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immunotolerance in the cardiology section. At the end of
this review, we propose future research directions to
identify the most appropriate children to list for transplan-
tation and to improve the post-transplant care of these
children.
& TRANSLATIONAL RESEARCH IN PEDIATRIC
RENAL TRANSPLANTATION
The Challenge of Antibody-Mediated Rejection
Kidney transplantation has had a long and successful
history since the human leukocyte antigen (HLA) was
discovered in the 1960s. The realization that graft rejection
was an immunological phenomenon resulted in the devel-
opment of immunosuppressive drugs, which allowed for
organ transplantation from genetically different donors (1).
Although the primary consideration in tissue and organ
transplantation is to ensure ABO blood group compatibility,
large national databases suggest that graft survival improves
with better HLA antigen matching and that this matching
is an important factor in long-term graft survival (2,3).
The establishment of the International Histocompatibility
Workshop in 1965 set the stage for histocompatibility testing
in transplantation. In the ensuing years, the techniques and
standardization of HLA typing evolved, and new antigens
were characterized. In recent years, molecular technology has
improved the accuracy and reproducibility of tissue typing,
cross-matching, and detection of anti-HLA antibodies (4,5).
In the 1960s, immediate allograft failure was found to
decrease markedly with negative cross-matching between
donor lymphocytes and recipient serum. This finding
eventually resulted in the development of the comple-
ment-dependent cytotoxicity assay (6,7). Although immu-
nosuppressive therapy regimens and the short-term
survival of kidney allografts have improved substantially
since then, acute rejection in the first year and chronic
allograft nephropathy continue to be major determinants of
long-term graft survival (8). Traditionally, transplant rejec-
tion has been considered to be predominantly mediated by
T-cells. However, increasing evidence suggests that inade-
quate control of the humoral arm of the immune system
contributes to chronic allograft nephropathy (9).
Halloran et al. first described an atypical form of acute
rejection occurring a few days to weeks after transplantation
that was characterized by a rapid deterioration in renal
function and a high incidence of failure in a previously
functioning graft. Pathologic features were similar to
hyperacute rejection and were associated with donor-
specific HLA antibodies (10,11). This phenomenon has since
been termed AMR (12,13).
Traditionally, the complement-dependent cytotoxicity
cell-based assay was used to detect donor-specific anti-
HLA antibodies and was useful in predicting hyperacute
rejection. However, this assay is not sensitive enough to
detect low or marginal titers of antibodies, which are
relevant to the early outcomes of the transplant. The advent
of solid-phase assays (SPA), which have greater sensitivity
and specificity, has resulted in increased identification of
AMR (14). The incidence of AMR is less than 5% in
unsensitized patients but between 40% and 90% in
sensitized patients (15). The strength of the antibody
response appears to be strongly associated with the risk of
rejection (14-17). Occurring from preformed or new anti-
HLA antibodies, AMR generally has a worse prognosis and
requires different management than does T-cell-related
rejection (18).
A higher degree of HLA mismatches, acute rejection
episodes, patient nonadherence to treatment, inadequate
immune suppression, previous organ transplantation, blood
transfusion, and pregnancy result in sensitization and
increased risk for AMR. The first six causes are important
in children (14,18,19). Currently, 17% of patients with end-
stage kidney disease on the waiting list for kidney
transplants have had previous transplants. Given that 50%
of all childhood kidney transplant recipients will receive
a second kidney transplant by the age of 25 years, a
substantial proportion of children will be sensitized as
young adults (20). The true incidence and prevalence of
AMR in children is not known.
Clinical Features of Acute and Chronic Antibody-
Mediated Rejection
In acute AMR, patients present with an acute loss of graft
function, most often in the first few weeks after transplanta-
tion. The clinical presentation is indistinguishable from
acute cellular rejection. It can also occur years after
transplantation when immune suppression is decreased or
stopped, either iatrogenically or because of nonadherence
by the patient (21). It can occur in both sensitized patients
and in those with a negative pre-transplant cross-match.
Chronic AMR is an insidious process associated with
fluctuating levels of donor-specific antibodies (DSAs) and
results in irreversible structural damage. Clinically, it
manifests as proteinuria, hypertension, and declining graft
function over time.
New Diagnostic Approaches to Antibody-Mediated
Rejection
In the past decade, there have been major technologic
advances in assays that detect anti-HLA antibodies. Solid-
phase assays and the use of single HLA antigen beads have
increased the sensitivity and specificity of detection.
Knowing the presence and specificity of anti-HLA anti-
bodies in organ transplant candidates is important for
identifying compatible donors, interpreting cross-match
results, and assessing the risk of post-transplant rejection.
After transplantation, knowledge of anti-HLA antibodies
aids in diagnosing AMR and in monitoring alloreactive
antibodies (4,22). Therefore, these assays are useful for the
preemptive management of sensitized patients, who are at
high risk for AMR, and for managing AMR when it occurs.
Panel Reactive Antibodies
Highly sensitized patients are less likely to have a cross-
match–compatible donor and therefore have longer waiting
times on the deceased donor waiting list. The panel reactive
antibody test estimates the likelihood of finding a cross-
match–compatible donor using a panel of normal blood
donors. The calculated score is the percentage of donors
in this pool to whom a patient has reactive antibodies.
Analysis of antibody specificity by SPAs has helped
determine unacceptable donor antigens to which the patient
has previously been sensitized and forms the basis for the
calculated panel reactive antibody (cPRA) and virtual cross-
match. The cPRA represents the percentage of donors that
will be preemptively declined because of the presence of
unacceptable antigens and has been found to increase the
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efficiency of organ allocation, increase the identification of
compatible donors, and increase the likelihood of successful
transplantation in sensitized patients (23,24). Knowledge of
the HLA antibody specificity of the recipient and the HLA
type of the potential donor can predict compatibility, a
process called the ‘‘virtual cross-match.’’
Donor-Specific Cross-matching
Donor-specific cross-matching directly measures the
reactivity of the patient’s serum to the donor cells. The
development of flow cytometry has increased the sensitivity
of cross-match testing.
N The complement-dependent cytotoxicity assay is a
traditional cell-based assay that determines whether
the donor and recipient are compatible and helps predict
immediate graft loss from hyperacute or accelerated
rejection. The limitations are that it may detect non-HLA
antibodies that are not necessarily harmful, such as
autoantibodies and IgM antibodies. The sensitivity is
low, so there are false negative reactions, and distin-
guishing class I and class II antibody specificities is
difficult (4,22).
N Flow cytometry cross-matching is an antibody-binding
assay that detects antibodies to HLA antigens on the
surface of target cells. It is more sensitive than the
complement-dependent cytotoxicity assay in detecting
low-titer complement-fixing and non-fixing antibodies
and IgG sub-types associated with an increased risk of
allograft rejection. Some centers have abandoned the
complement-dependent cytotoxicity cross-match and
instead use flow cytometry and solid-phase binding
assays exclusively.
N The ELISA cross-match test with donor antigen uses
purified HLA molecules from the donor, which are
bound to a well in a microtiter plate. HLA antibody is
then detected by an enzyme-linked immunosorbent
assay.
Antibody Assays
Solid-phase assays (SPAs), such as flow PRA and flow-
specific beads that use purified HLA antigens attached to
microparticles, can detect anti-HLA antibodies missed by
the complement-dependent cytotoxicity assay. They allow
for better definition of B-cell cross-matches, which have
been attributed to non-HLA-specific autoantibodies in the
past. A positive B-cell cross-match from class I and II HLA
antibodies can result in acute AMR. Antibodies to HLA DP
antigens have been associated with acute rejection. SPAs
help identify these antigens because donors are not
routinely typed for HLA-DP antigens.
In summary, techniques more sensitive to anti-HLA
antibodies allow for early recognition of the risk of allograft
injury from AMR and for preemptive management. A
concern with SPAs is the clinical relevance of the low-level
anti-HLA antibodies that they detect, which may not always
be harmful. Therapy with monoclonal antibodies can also
interfere with the assays. These tests have to be interpreted
in the context of the clinical presentation (4).
The HLA Matchmaker program was developed to review
each HLA antigen as a string of epitopes. Because
antibodies are induced only against a small proportion of
immunogenic epitopes, this information is useful in
determining HLA compatibility at a molecular level and
can identify acceptable mismatches (25,26).
Risk Assessment and Diagnosis of Antibody-
Mediated Rejection
Donor-specific antibodies can occur in the sensitized
individual (before transplant) or in the unsensitized
individual after transplant. In living donors, preformed
antibodies can be detected before transplant, whereas in
deceased donors, the target antigens may not be known
in advance, although they can be detected retrospectively.
Kidney transplant recipients can also develop new (de novo)
HLA and non-HLA antibodies after transplantation, even
when they were at low immunological risk before transplant
(9,14,27,28).
The development of de novo antibodies increases the risk
of acute and chronic graft injury, which occurs at a median
of 2 years after transplant in children (14,28). The frequency
of occurrence is variable and depends on the sensitivity of
the assay, the type of immune suppression, and the patient.
Anti-HLA antibodies often develop before allograft injury
(28). Patients with de novo DSAs have a higher risk of acute
rejection, higher creatinine concentrations, proteinuria, and
a higher incidence of graft loss (14). De novo DSAs are
usually class II antibodies and are associated with a worse
prognosis than are class I HLA antibodies (9,28).
Studies in animals and humans have found that T-cell
recognition of the processed antigen through the indirect
pathway activates the humoral response (29). However, not
all patients with anti-HLA antibodies have acute rejection or
graft loss. Sutherland et al. developed a C1q assay that
detects complement binding DSAs, and they hypothesized
that complement activation by DSAs may be important in
initiating tissue injury (30). Patients with C1q-binding DSAs
were more likely to have allograft injury and loss than
were patients with non-C1q-binding DSAs (30). Antibody-
mediated rejection can be caused by antibodies to major
histocompatibility complex (MHC) class I chain-related
gene A and gene B (MICA and MICB), angiotensin type I
receptors, endothelial antigens, and vimentin, which is a
cytosolic protein (Table 1) (31).
Table 1 - Target Antigens in Antibody-mediated Rejection
of Renal Transplants in Children.
Target Antigen Antigen Subgroup
Major HLA1 Antigens
Class I
Class II
Minor HLA1 Antigens
MICA2
MICB3
Non-HLA1 Antigens
Angiotensin II type I receptor
Endothelial and monocyte antigens
Vimentin
Agrin
Percalan
Collagen types 4 and 6
Myosin
ABO Blood Group Antigens
1Human leukocyte antigen
2Major histocompatibility complex class 1-related chain A
3Major histocompatibility complex class 1-related chain B
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Pathology of Antibody-Mediated Rejection
In AMR, alloantibodies preferentially attack the peritub-
ular capillaries and glomerular capillaries; by contrast, T
cell-mediated rejection involves tubular, interstitial, and
intimal infiltration of inflammatory cells (32-34). Acute
cellular rejection can coexist with acute AMR. In many
circumstances, AMR is mediated by activation of the
classical complement pathway. The C4d biomarker is a
degradation product of activated C4b, which is a classical
component of complement. It is covalently bound to tissues
and deposited in peritubular capillaries in AMR. C4d is
diagnosed by immunohistologic staining. It is strongly
associated with DSAs, helps confirm the diagnosis, and is
the best marker of complement-fixing circulating antibodies
[Figure 1A and 1B (34-36)].
Antibodies to class I and II HLA antigens are found in
88% to 95% of patients with C4d deposition and acute graft
dysfunction (36). The deposition of C4d without circulating
antibodies can be the result of absorption by the graft, as
was proven by eluting anti-HLA antibodies from rejected
grafts (21). Additional staining with C3d, a cleavage product
of the complement component C3, may be useful in some
cases (37). C4d deposition can occur beginning several years
after transplantation, even though previous biopsies were
C4d negative (34,38). C4d deposition is found in 2% to 26%
of ABO-compatible, histologically normal renal allografts.
The long-term importance of this deposition is unknown
(39). Antibody-mediated rejection has been detected in C4d-
negative grafts, and in such cases, evidence of microcircu-
latory injury and the presence of class II DSAs portend a bad
outcome (40).
The Banff criteria for diagnosing AMR are (41):
1) Circulating antibodies to donor MHC antigens,
2) Diffuse deposition of the complement split product
C4d in peritubular capillaries as an indicator of
antibody activity (.50% of peritubular capillaries),
3) Morphologic indications of acute tissue injury, and
4) Clinical evidence of graft dysfunction.
Morphologic evidence of acute tissue injury includes 1)
acute tubular injury, 2) neutrophils or monocytes in the
peritubular capillaries or glomeruli, and 3) intimal arteritis,
intramural or transmural inflammation, or fibrinoid necro-
sis of the arteries. Antibody-mediated rejection is diagnosed
in 1% to 6% of protocol renal biopsies in unsensitized
patients and in 60% to 70% of patients with suspected acute
rejection (34,38). Protocol biopsies have revealed diffuse
peritubular capillary staining with C4d and DSAs with no
histological evidence of injury. The importance of this
finding is not clear, but some authors postulate that there
may be accommodation to the graft (32,35). Accommodation
is the acquired resistance of the allograft to immune-
mediated injury (42).
Chronic AMR is characterized by injury to the glomerular
and tubular basement membrane. Capillary injury is
considered the initiating event, as evidenced by an up-
regulation of the endothelial antigen, PV1 (plasmalemmal
vesicle associated protein 1) (43). The glomerular lesion is
termed ‘‘transplant glomerulopathy’’ and is characterized
by thickened capillary loops and double contours. On
electron microscopy, the glomerular basement membrane
(GBM) shows reduplication and lamination. There are peri-
tubular basement membrane multilayers with margination
of mononuclear leukocytes. Ultimately, the peritubular
capillaries are destroyed, resulting in tubular atrophy and
interstitial fibrosis (44,45).
Transplant glomerulopathy has been described as the
‘‘ABCD’’ tetrad: Anti-donor antibodies, capillary Basement
membrane multilayering, C4d deposition, and GBM
Duplication (44). C4d deposition may or may not be present
in chronic AMR, and donor-specific antibody concentrations
usually fluctuate.
Other than these findings, complement-independent
mechanisms caused by antibodies with specificities to
MHC class II (expressed constitutively in the endothelial
cells of capillaries in human kidneys) or a mixture of class I
and II anti-HLA antibodies are also associated with AMR
(46,47). Platelet activation upregulates MHC class I and II
antigens on endothelial cells, which then release factors
Figure 1 - A) A 4-year-old child who had good allograft function initially and then developed acute antibody-mediated rejection 2
weeks after deceased donor kidney transplantation. Renal biopsy reveals marked acute tubular necrosis and interstitial hemorrhage.
There is evidence of glomerulitis and tubulitis (H&E, 406). B) Immunofluorescence in this patient reveals diffuse C4d staining of the
peritubular capillaries, supporting the diagnosis of acute antibody-mediated rejection.
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that activate T-cells (48). Elevated endothelial- and adhe-
sion-molecule-associated gene transcripts and antibodies
against the GBM are implicated in the morphologic lesion of
transplant glomerulopathy (49,50).
Small animalmodels of cardiac transplantation are frequently
used because of the ease of surgery and vigor of rejection,
although the concept of AMR is controversial in cardiac
transplantation. Animal models suggest that the lesions occur
because of chronic endothelial cell injury, and B-cell-deficient
mice do not develop fibrous chronic allograft nephropathy (51).
However, these models are limited by antigenic differences
between murine and human organs (29,52).
ABO-Incompatible Renal Transplant
Historically, one of the main barriers to living kidney
donation has been ABO incompatibility. In Japan, because
of the lack of deceased donors, ABO-incompatible donors
have been used in kidney transplantation, spurring the
development of aggressive immunosuppressive protocols
(53). The three-year survival in ABO-incompatible trans-
plants in adults is similar to that of ABO-compatible kidney
transplants. According to the 2010 report of the North
American Pediatric Renal Trials and Collaborative Studies,
0.6% of childhood transplants are across ABO barriers (54).
The main problem with ABO-incompatible transplants is
the development of hemagglutinin antibodies to blood
groups not present in the recipient (53,55,56).
Decreasing hemagglutinin antibody titers, caused by
B-cell depletion therapies before transplantation, has
improved the short- and mid-term survival of children
with kidney transplants (53). Strategies to decrease these
titers include treatment with rituximab, splenectomy,
immunoadsorption of hemagglutinin antibodies, and
intravenous immunoglobulin (IVIG) before transplant.
However, acute rejection rates are higher than with ABO-
compatible transplants, and long-term outcomes remain to
be established (57).
New Therapies for Antibody-Mediated Rejection
Sensitization to HLA antigens limits access to and the
success of transplantation. Pre-transplant desensitization
protocols have made it possible to convert positive anti-
HLA cross-matches to negative, thus enabling transplanta-
tion in patients who otherwise could not have undergone
transplantation. These patients can be managed with
desensitization before transplant and treatment of AMR
after transplant. Apheresis and IVIG-based protocols can
convert a positive lymphocytotoxic cross-match to a
negative one before transplant. These protocols have led
to higher transplantation rates and improved short-term
graft survival. Despite such protocols, however, many
patients continue to experience clinical and subclinical
AMR after transplant (14).
The protocols used for pre-transplant desensitization and
post-transplant treatment of acute AMR are similar and are
based on four concepts.
1. Eliminating or reducing circulating antibodies
2. Inhibiting residual antibodies
3. Suppressing or depleting B-cells
4. Suppressing T-cell response
Plasmapheresis can reduce the total IgG HLA antibodies.
In one case series, some patients required 15 to 30 sessions
of plasmapheresis, alternating with IVIG, to substantially
lower antibody titers (58). However, these treatments also
remove clotting factors and require replacement with fresh
frozen plasma and albumin. Anemia requiring packed red
cell transfusion, bleeding diathesis, allergic reactions, and
blood-borne infections are some of the complications
associated with plasmapheresis. A Sepharose-bound sta-
phylococcal protein A column with a high affinity for
binding IgG is used in immunoadsorption. This technique
has higher specificity compared with plasmapheresis and
does not require replacing large volumes of plasma. Most
columns used in Europe and Japan are not approved by the
FDA (14). However, anti-HLA antibodies may rebound to
baseline or higher levels a few weeks after both plasma-
pheresis and immunoadsorption.
Inhibiting Residual Antibodies
Intravenous immunoglobulin inhibits the immune res-
foponse in several ways, including neutralizing anti-HLA
antibodies and inhibiting complement (14). Various proto-
cols have been used to inhibit antibodies. Montgomery et al.
used low-dose IVIG (100 mg/kg/day), alternating with
plasmapheresis, as part of their desensitization and treat-
ment protocol (58). The University of Maryland protocol
uses 6 sessions of plasmapheresis, triple immune suppres-
sion, and low-dose IVIG after each plasmapheresis in living
kidney donors (59).
Jordan et al. initially used high-dose IVIG at 2 g/kg/
month until cross-matching was negative (60,61). However,
they subsequently modified the protocol to 2 doses of IVIG
and 1 dose of rituximab (62). The advantage of this method
is its applicability to patients on the deceased donor list. A
report of the use of high-dose IVIG in 2 highly sensitized
patients showed both to be rejection-free with excellent
renal function at 15 and 19 months, respectively (25).
Despite these desensitization protocols, the incidence of
AMR remains high in the first year after transplant because
these protocols have no effect on memory B-cells.
Suppressing or Depleting B-cells
Rituximab is a chimeric humanized monoclonal antibody
against the cell surface marker, CD20, which is expressed in
pre-B and mature B-cells. Rituximab destroys CD20-positive
cells in several ways, including antibody-dependent cell-
mediated cytotoxicity, complement-mediated cytotoxicity,
and apoptosis. Rituximab is generally combined with
plasmapheresis, IVIG, or both because it is not effective
against antibody-producing plasma cells if used alone
(13,14,18,21). The response to rituximab in chronic anti-
body-mediated-rejection is variable, and there is currently
no way to distinguish responders from nonresponders (63).
Infectious complications can increase when rituximab is
used with other powerful immunosuppressive agents, such
as anti-thymocyte globulin.
Splenectomy immediately reduces the B-cell and plasma
cell pool and has been used as a last resort for salvaging
transplanted kidneys (64,65). It has also been used in highly
sensitized patients in whom desensitization therapy has
failed.
Other Therapies
Bortezomib, a proteosome inhibitor, is effective against
antibody-producing plasma cells that induce apoptosis
and has been successfully used with plasmapheresis and
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rituximab to treat children undergoing heart transplant (66).
Plasmapheresis removes only some of the alloantibodies,
and re-equilibration with extra vascular antibodies occurs in
48 to 72 hours. Rituximab blocks CD20-positive cells, and
plasma cells do not express this marker. Therefore,
bortezomib is useful in blocking anti-HLA antibody
production. However, bortezomib alone may not be
sufficient to reduce anti-HLA antibody levels because it
requires activated plasma cells, such as those present in
acute AMR (67). Moreover, it may not sufficiently target
memory B-cells.
Eculizumab is an anti-complement C5 humanized mouse
monoclonal antibody that prevents the formation of the
membrane attack complex. It is based on evidence that
activation of the terminal component of complement is
necessary for the development of acute antibody-mediated
rejection. It has been used as a rescue therapy in patients not
responding to other treatments for AMR (68,69). Infectious
complications, such as polyoma virus type BK nephritis,
have been reported after its use. Stegall et al. reported
decreased rates of acute and chronic AMR after treatment
with eculizumab (69). Eculizumab does not affect DSA or
C4d deposition, but it does decrease tissue injury and graft
dysfunction (70). Experience with this drug is currently
limited.
C1 inhibitor therapy may eventually be an option for
treating refractory AMR. Its use is based on the theory that
C1q-binding DSAs harm the allograft (71).
Secondary Immunodeficiency
While several reports have concluded that immunomo-
dulatory therapies, such as IVIG–rituximab desensitization,
do not significantly hinder cell-mediated or humoral
immunity (72,73), the potential immunologic consequences
of these and newer therapies used in desensitization or
‘‘antibody reduction therapies’’ (74) should not be over-
looked, especially with long-term immunosuppression.
Secondary immunodeficiency can be clinically significant,
and it presents with recurrent fungal, bacterial, or viral
infections, usually of the respiratory tract; however, it may
include gastrointestinal infections and increased autoim-
mune complications, depending on the extent of the
immune suppression. Infections, including CMV, BK virus,
and parvovirus B19, have been treated with IVIG in the
post-transplant setting (74). The role of IVIG is both
immunomodulatory at high doses and immune replacing
at lower doses and may be required in the case of secondary
hypogammaglobulinemia. Immune replacement with IVIG
or subcutaneous immunoglobulin plays an important role in
the post-transplant period for patients with recurrent
infection because of secondary immunodeficiency. A
consultation with an immunologist to coordinate replace-
ment therapy may be an important part of the multi-
disciplinary approach. With regard to IVIG protocols to
prepare ‘‘sensitized’’ patients for transplant, a consensus
approach does not yet exist. However, IVIG has certainly
become a keystone of many empirically derived protocols,
and a recent review of IVIG use in solid organ transplanta-
tion endorsed its use in high-risk groups (75). An earlier
review published in the US also recognized the use of IVIG
in solid organ transplantation but cautioned that further
studies are necessary to optimize use for this indication
(76).
General Approach to Treating Acute Antibody-
Mediated Rejection
Data from children treated with AMR are scarce
(19,77,78). In highly sensitized patients, graft survival is
better after desensitization and transplantation. The
KDIGO (Kidney disease: improving global outcomes)
guidelines (strength of evidence 2C) suggest treating acute
AMR with some combination of plasma exchange, IVIG,
and anti-CD20 antibody, with or without corticosteroids
(79). Depending on the clinical response, a tiered approach
to management has been suggested by various authors
(Figure 2).
During treatment, antibody strength is monitored using
an SPA. Threshold values for antibody levels depend on
technical and immunosuppression protocols and are estab-
lished by individual transplant centers (14-17). Antibody
strength is measured by Luminex and is expressed as
the mean fluorescence intensity or molecules of equivalent
soluble fluorochrome. Antibody strengths are expressed as
medium channel shifts in flow cytometry. In acute AMR, the
mean fluorescence intensity values were greater than 5200
in most patients (14,17). Treatment is aimed at lowering the
strength of the antibody.
Treating chronic AMR is difficult, and the optimal
approach has yet to be identified because of its indolent
course. High-dose IVIG and rituximab given to children
with chronic AMR slowed the rate of decline in renal
function in a single-center study (19).
Other Pre-emptive Measures
Paired organ sharing, such as kidney-paired donation, is a
viable option when two donor-recipient pairs are blood type
or cross-match incompatible with their intended recipients.
The exchange of donor kidneys allows each donor to do-
nate a kidney and each recipient to receive a compatible
transplant. If this exchange works for specific donor-
recipient pairs, less-intense immune suppression and better
graft outcomes are expected (80).
Combined liver-kidney transplantation with a liver
allograft decreases rejection rates and promotes rejection-
free survival of the transplanted organs, even if the cross-
match is positive before surgery (81). Combined organ
transplantation has been extended to include partial
auxiliary liver transplantation to make kidney transplanta-
tion possible (82). However, AMR has been reported in the
renal allograft in highly sensitized patients (83).
Summary and Future Translational Research
Directions in Kidney Transplantation
Advances in molecular technology have increased our
knowledge and ability to manage sensitized individuals and
to recognize AMR. These advances have prompted the
evolution of various protocols to preemptively manage the
sensitized patient and have given us several options for
treating acute AMR. However, the persistence of memory
cells is a substantial barrier to management. We need to
better understand graft accommodation and therapies that
will increase tolerance to the graft. Appropriate manage-
ment of acute AMR and the sensitized patient may slow the
development of chronic AMR. Reprogrammed pluripotent
stem cells may also have enormous therapeutic potential (84).
Because endothelial injury is a prominent feature of AMR,
drugs like mycophenolate mofetil, angiotensin-converting
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enzyme inhibitors, statins, and aspirin could potentially
modulate endothelial cell function (85). We also need to
developmore sensitive, specific, and noninvasive biomarkers
of the onset of AMR.
Bench to Bedside in Recurrent FSGS
The role of translational science in bridging the gap
between ‘‘bench and bedside’’ is best demonstrated by the
progress in unraveling the mechanisms of recurrent disease
in renal transplantation. Perhaps the most ominous mechan-
ism has been recurrent FSGS, a non-immune podocytopathy
that is characterized by nephrotic-range proteinuria and
variable progression to end-stage renal disease. Approximately
10% of children undergoing renal transplantation have FSGS
as the primary diagnosis (86,87). Since FSGS was first
recognized in 1972, the incidence in various ethnic popula-
tions has remained approximately 30% (range, 20% to 67%)
(86,88,89). Although ‘‘late’’ recurrence may occur years after
transplantation, the most frequent and marked recurrence of
FSGS is with massive proteinuria when the graft is
reperfused at the time of surgery. If remission cannot be
achieved by medical intervention, the rate of graft loss
increases to more than 50% within the first year (90).
Early speculation that a ‘‘circulating permeability factor’’
(cPF) caused recurrent FSGS (R-FSGS) led to plasmapheresis
as a primary treatment with mixed success (91-93).
Plasmapheresis continues to be a component of both pre-
emptive and maintenance treatment for R-FSGS and has led
to the quest to identify circulating factors as new targets for
more effective treatments (92-95).
Efforts to identify cPF(s) have been arduous andhave involved
the complex collaboration of basic and clinical physician
scientists (96,97). Evidence for circulating factor(s) include:
1) The immediate recurrence of proteinuria when the
graft is reperfused (97,98).
2) The improvement in proteinuria when the presumed
cPF is removed with plasmapheresis or immunoad-
sorption (99,100).
3) The regression of FSGS when a kidney with recurrent
FSGS is re-transplanted into a patient without FSGS
(101).
4) The induction of proteinuria in animals injected with a
patient’s sera or with specific cPF (102-104).
5) The destruction of the podocyte foot process observed in
transplanted kidneys biopsied within 1 to 2 hours after
reperfusion in patients with recurrent proteinuria (105).
6) The disruption of the actin cytoskeleton in normal
human podocytes exposed to sera from patients with
R-FSGS or to currently suspected cPFs (106,107).
Savin et al. pioneered the development of an assay to
identify the character and function of the cPF by studying
the sera from patients with R-FSGS (96). They developed an
in vitro biological assay of glomerular permeability
(91,92,96). Isolated rat glomeruli are incubated with a
patient’s serum, plasma, or plasma fraction. The perme-
ability of albumin to the glomerular membrane is deter-
mined and expressed as the ‘‘albumin permeability index’’
(Palb), which ranges from zero in normal control serum to
1.0 for maximal induced injury. A Palb greater than 0.5
indicates marked injury to the glomerular protein barrier
and is not specific to FSGS (92). For example, circulating
cytokines and inflammatory markers, such as TNFa and
b-1-integrin, may also generate a Palb greater than 0.5. In
patients at high risk for recurrence and in those with rapid
progression to end-stage renal disease, a Palb greater than
0.5 has been highly predictive of outcomes (92,96). The cPF
was further characterized by concentrating patient samples
and applying protein isolation and fractionation techniques
to obtain a molecular weight between 30 and 50 kD (108).
More recently, the Savin group has identified cardiotrophin-
like cytokine-1 (CLC-1) as a potential candidate cPF protein,
but further studies are required (109).
A parallel effort using research in molecular biology,
genetics, and clinically applicable mechanistic studies
has been directed to understand the pathophysiology of
proteinuria and is grounded in the work of Mundel and of
Figure 2 - Schematic diagram depicting a suggested algorithm for the management of acute antibody-mediated rejection. T cell-
mediated and antibody-mediated rejection can often coexist, and treatment may need to address both. Surveillance for viral infections
should be intensified, and the use of anti-viral and antibiotic prophylaxis is important during treatment. The benefits of escalating
treatment should be weighed against the risk of infection and malignancy.
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Reiser and colleagues (106,107,110,111). Much of this
research has taken place at the University of Miami
Transplant Institute during the past decade and has led to
an intense global collaboration with physician scientists
caring for patients with both primary and recurrent FSGS
(110-115).
The integrity of the podocyte is paramount in maintaining
the ‘‘barrier’’ against proteinuria and in the evolution of
many progressive kidney diseases (110,111). This complex
genetic, anatomic, and physiologic pathogenesis has become
better understood during the past decade. The fundamental
research began with Reiser et al. (110), who discovered the
relationship between the stimulation of a receptor on the
podocyte, termed the ‘‘B7-1’’ (also known as CD80), that,
when stimulated in various pathologic settings, disrupted
the integrity of the podocyte cytoskeleton and led to
pathologic proteinuria and nephrotic syndrome (110).
In a summary of recent discoveries, Mundel and Reiser
emphasize the basic physiology involved in the proteinuria
and identify potential therapeutic targets (111). They
hypothesize that there may be a common pathologic
pathway involving the enzymatic cleavage of regulators of
the podocyte actin cytoskeleton by cytosolic cathepsin L
(111). This cleavage disrupts the podocyte actin cytoskeleton
and causes the clinical syndrome of nephrotic proteinuria.
In the early stages of nephrotic proteinuria, as in R-FSGS,
these changes are potentially reversible. In essence, this
work forms the basis of new discoveries in the pathogenesis
and development of therapeutic targets for early interven-
tion (116).
With this active translational research, the microanatomy
of the podocyte has been elaborated, and a number of
genetic, immune, and nonimmune diseases of the podocyte
have been described (117,118). In concert with these
discoveries has been the rapid and exciting evolution of
potential therapies (109-115). New insights into the cause-
effect relationship between cPF and podocyte injury in
recurrent FSGS have come from identifying the soluble
urokinase receptor (suPAR) as a cPF that can cause
podocyte injury in recurrent FSGS (106,107) and from the
discovery that sphingolipid-related enzymes are markedly
affected in podocytes in R-FSGS (115). Other discoveries
include the nonimmune target mechanism of action of
cyclosporine (111,112) and rituximab (115) in preventing
and modulating FSGS recurrence. Most recently, in our
institution, four patients with severe R-FSGS who were
nonresponsive to multiple interventions with plasmapher-
esis, rituximab, and calcineurin inhibitors responded to the
specific B7-1 receptor inhibitor, abatacept, with resolution of
their proteinuria (119).
Despite recent advances in research related to primary
and recurrent FSGS, observational and therapeutic trials are
needed to better understand and treat this complex disease.
Among the current studies are the NEPTUNE and FONT2
trials. The NEPTUNE (Nephrotic Syndrome Study
Network) is a multicenter, observational trial whose
purpose is to characterize the complex disease known as
‘‘steroid-resistant nephrotic syndrome.’’ The National
Institutes of Health and private foundations, including the
NephCure Foundation, fund it. FONT2 is a randomized,
phase II trial comparing the efficacy of galactose with that of
adalimumab for treating steroid-resistant FSGS (120).
In summary, scientific advances in understanding the
pathogenesis of FSGS and its recurrence after kidney
transplant during the past decade have enabled the
introduction of targeted therapies designed to improve
patient outcomes.
& TRANSLATIONAL RESEARCH IN PEDIATRIC
CARDIAC TRANSPLANTATION
Allograft rejection and complications related to the
immunosuppression necessary for the survival of the
transplanted organ remain the major causes of morbidity
and mortality in cardiac transplant recipients. The mechan-
isms of cardiac transplant rejection are similar to those of
other solid-organ rejections and can be manifested through
three modalities (121).
1) Acute cellular rejection mediated through T-cells
invading and destroying allograft tissue.
2) AMR mediated through complement activation and
triggered by antibodies directed against the HLA
antigens of the donor.
3) Cardiac allograft vasculopathy (CAV) characterized by
intimal thickening and remodeling of the coronary
arteries. This type of rejection usually occurs many
years after transplantation and is a major limiting factor
in long-term allograft survival.
Currently, endomyocardial biopsy is the reference stan-
dard for detecting graft rejection. However, it is invasive
and limited by sampling error and interobserver variability.
Additionally, Nakhleh et al. have established that histolo-
gical expression of rejection is patchy in autopsied heart
allografts; the foci of rejection were surrounded by large
areas of intact myocardium (122). Other drawbacks of
endomyocardial biopsy include the need for multiple
samples to increase sensitivity, the inability to detect graft
events in the period between biopsies, and its high cost
(121). Endomyocardial biopsy also has complications, albeit
rare, such as damage to the vessels, arrhythmias, conduction
abnormalities, biopsy-induced tricuspid regurgitation, and
even cardiac perforation (123-127).
Over the past few years, clinicians have looked into other
noninvasive diagnostic tools, such as Doppler echocardio-
graphy (128,129), high-resolution electrocardiography (130),
intramyocardial electrography (131), scintigraphy to detect
antimyosin antibodies (132), and gene expression profiling
in peripheral blood lymphocytes (133). Narula et al. studied
the imaging of technetium-labeled annexin V using gamma
cameras. Annexin V is an endogenous protein with a high
affinity to phosphatidylserine, which is a phospholipid
released during apoptotic cell death. The uptake of annexin
V by the myocardium was associated with moderate grades
of allograft rejection, suggesting the use of this imaging
technique to detect rejection (134). However, although they
may be able to detect rejection, these methods are not as
effective as endomyocardial biopsy.
Identifying biological markers that can quickly, accurately,
and noninvasively detect different types of rejection may
improve the management of cardiac transplant patients.
Biomarkers are becoming more important because they are
effective in monitoring biological processes, helpful in
diagnosing and monitoring disease progression, and useful
in assessing the response to treatment. Characterizing a
disease process through biomarkers may help tailor treat-
ment to individual patients and indicate their prognosis.
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Biomarkers are anatomic, biochemical, or molecular
characteristics of body fluids or tissues that indicate or are
associated with clinically meaningful changes in physiology
(135). To be clinically useful, they should be easily acquired
and measured, valid, and have a sensitivity and specificity
greater than other relevant technologies. They should also
be relatively inexpensive and directly related to treatment
decisions. Their validity should be established in prospec-
tive multicenter studies (136).
In the field of transplantation, the use of biomarkers is
rapidly evolving in two areas: 1) predicting and detecting
allograft rejection and 2) detecting allograft tolerance for
directing the weaning and proper adjustment of immuno-
suppression (135).
Overview of Rejection and Cardiac Biomarkers
Rejection of the transplanted heart starts as a proinflam-
matory state that ultimately leads to graft failure marked by
the signs and symptoms of heart failure. The immunological
mechanism of rejection begins when recipient T-cells
recognize the graft antigens by non-self MHC type I and
type II antigens and by the recruitment of cytotoxic T-
lymphocytes. The CD4+ T-cells then help the B-lymphocytes
to produce antibodies against the MCH antigens. This step is
followed by the release of chemical mediators and cytokines
and the further proliferation and differentiation of T- and
B-lymphocytes, which creates a vicious cycle of inflammation
and alloreactivity. The combined actions of the T-cells,
antibodies, and natural killer cells cause inflammation,
necrosis, and fibrosis in the myocardium (137).
The current knowledge about biomarkers for detecting
allograft rejection is derived from markers of different
pathophysiologic processes, such as cardiac failure. We
review below some of the biomarkers for inflammation,
cardiomyocyte injury, and cardiomyocyte stress that have
some potential to detect early rejection episodes in cardiac
transplantation.
Inflammation
The first biomarker of inflammation was C-reactive
protein (CRP), discovered in 1954 (6). A member of the
pentraxin superfamily, CRP is a prototypical ‘‘acute phase’’
protein that is synthesized at a low rate under physiologic
conditions but that is markedly induced and secreted
after tissue injury and inflammation (138). It is produced
predominantly by hepatocytes under the influence of
cytokines, such as IL-6 or TNF-alpha.
In 1956, Elster et al. found elevated concentrations of
CRP in patients with heart failure, and those with higher
concentrations had more severe disease (139). Since then,
many studies have verified that CRP is an important
biomarker of inflammation. It became widely used when
Ridker developed a low-cost and high-sensitivity assay in
2001 (140).
Venugopal et al. determined that CRP directly affects
vascular endothelium by reducing nitric oxide release,
increasing endothelin-1 production, and inducing the
expression of endothelial adhesion molecule (141).
More recently, in a prospective observational study of 79
cardiac transplant recipients, Dolz et al. measured various
inflammatory markers, such as fibrinogen, IL-6, TNF-alpha,
sialic acid determinants, and CRP in endomyocardial
biopsies performed during the first year after transplant.
They concluded that CRP had the largest area under the
ROC curve, with concentrations less than 0.87 mg/dL being
90% specific for rejection and concentrations greater than
7.3 mg/dL being 100% sensitive for rejection. They identi-
fied CRP as the most useful biomarker for the noninvasive
screening of acute cellular rejection in the first year after
heart transplantation (142). However, because its level is
elevated in many inflammatory states, CRP is a nonspecific
marker and does not always indicate cardiac rejection alone.
Cardiomyocyte Injury
Cardiomyocyte injury results from a variety of factors,
such as ischemia, inflammation, neurohormonal activation,
and oxidative stress. Over the past two decades, myofi-
brillar proteins —the cardiac troponins I and T—have
emerged as sensitive and specific markers of cardiomyocyte
injury and have proven useful in stratifying the risk of
coronary syndromes.
In a recent pilot study, Dyer et al. evaluated the use of a
high-sensitivity assay for cardiac troponin to detect acute
graft rejection (AR) in children with heart transplants.
Plasma samples for measuring cardiac troponin T were
drawn at the same time as endomyocardial biopsy. Children
with AR had much higher cardiac troponin T levels than
those without AR. On follow-up, troponin concentrations
decreased as the rejection was resolving. These researchers
concluded that cardiac troponin could be a useful biomarker
for monitoring rejection in transplant recipients (143).
Cardiomyocyte Stress
Several other biomarkers of myocardial stress have been
studied. Brain natriuretic peptide (BNP) is a 134-amino acid
molecule synthesized by cardiomyocytes in response to
ventricular dilatation and increased wall tension. It is then
cleaved into pro-hormone BNP, which consists of 108 amino
acids. A circulating endoprotease, termed ‘‘corin,’’ further
cleaves the pro-hormone into two polypeptides: the inactive
N-terminal proBNP (NT-proBNP) and the bioactive peptide
BNP (144).
The physiologic effects of BNP include arterial vasodila-
tation, diuresis, natriuresis, inhibition of the renin-angio-
tensin-aldosterone system, and inhibition of sympathetic
nervous activity (144). Today, BNP and NT-proBNP are the
most widely used biomarkers for heart failure and are being
evaluated for their ability to detect graft rejection in patients
with cardiac transplants.
In a retrospective study of 85 children with heart
transplants, Rossano et al. evaluated BNP as a screening
tool for acute rejection. They measured BNP concentrations
at the time of endomyocardial biopsy. In the first year after
transplant, the median BNP concentration in children with
acute rejection was 387 pg/mL, whereas children without
rejection had a median concentration of 66 pg/mL. A
concentration of 100 pg/mL corresponded to 85% sensitiv-
ity and a 97% negative predictive value for detecting
rejection. At BNP levels above 100 pg/mL, the sensitivity
and negative predictive value for detecting acute rejection
1 year after transplantation increased to 95% and 99%,
respectively. The authors conclude at that more than 1 year
after transplantation, children with a BNP level of greater
than 100 pg/mL had less than a 1% chance of experiencing
acute rejection and that BNP can eliminate the need for
endomyocardial biopsies for surveillance in some cases
(145).
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Dyer et al. were the first to study NT-proBNP as a
biomarker of graft rejection in children receiving trans-
plants. In this prospective observational study of 42 children
(mean age, 11 years), high-sensitive cardiac troponin T
(hscTnT) and NT-proBNP were assayed at the time of
endomyocardial biopsy. Acute rejection was defined as an
International Society for Heart & Lung Transplantation
(ISHLT) grade of 2 or higher. Median (25th to 75th percentile)
hscTnT and NT-proBNP concentrations were higher in
children with acute rejection than in those without: hscTnT,
66 (45 to 139) vs. 7 (2 to 13) pg/mL; p= 0.001 and NT-
proBNP, 11,169 (280 to 23,317) vs. 334 (160 to 650) pg/mL;
p,0.01). They concluded that elevations in NT-proBNP
concentrations are associated with episodes of rejection in
these children (143).
Chronic Rejection and Cardiac Allograft
Vasculopathy
Allograft vasculopathy is a form of chronic rejection that
is associated with graft failure and re-transplantation in
both adults and children after heart transplantation
(146,147). There is clearly a need to understand and detect
this process as early as possible.
Allograft vasculopathy is characterized by remodeling of
the coronary arteries through diffuse fibromuscular intimal
hyperplasia and focal atherosclerosis. Endothelial damage is
caused by a combination of alloimmune and non-alloim-
mune responses and other factors that induce endothelial
activation and death. Endothelial damage is concomitant
with endothelial repair. During this process of damage and
repair, apoptotic circulating endothelial cells and endothe-
lial microparticles are released into the circulation. During
the regeneration process, endothelial progenitor cells are
released. All these circulating endothelial components may
become useful biomarkers of CAV (148).
Singh et al. studied 52 cardiac transplant patients under-
going coronary angiography between 5 and 15 years after
transplant. In a logistic regression model, apoptotic circulat-
ing endothelial cells (p=0.011) and apoptotic endothelial
microparticle concentrations (p= 0.014) were independent
predictors of vasculopathy (C statistic, 0.86; 95% confidence
interval, 0.76 to 0.95). This research is an initial step in
predicting CAV and in determining the need for coronary
angiography and intravascular ultrasound when it is
suspected.
Biomarkers of rejection have been evaluated in several
studies. However, the need for larger, multicenter trials
remains. Validated biomarkers will detect allograft rejection
before acute clinical decompensation and graft failure.
However, few biomarkers have yet become commercially
available.
In addition to detecting early rejection, clinicians must
also manage the severe immunosuppression required for
these transplant recipients. In the next sections, we review
the present and future efforts being made to address this
challenge.
Tolerance in Transplantation
Rejection of a transplanted allograft is an immunologi-
cally mediated process that occurs because of differences
between donor and recipient concentrations in HLA.
Allorecognition is the term for the immunological recogni-
tion of histo-incompatible antigens between genetically
disparate individuals from the same species. Alloresponse
in transplantation is the beginning of an adaptive immune
response in which allospecific T-cells are recruited. This
alloresponse rejects the transplanted organ in nontolerant or
inadequately immunosuppressed individuals (149).
To protect against alloresponse, cardiac transplant reci-
pients must take immunosuppressive medications, which in
the long run increase their susceptibility to infection,
malignancy, and accelerated cardiovascular disease, thereby
increasing their morbidity and mortality.
A new direction in preventing alloresponse has been to
induce ‘‘transplant tolerance,’’ which would avoid the need
for immunosuppression and its associated adverse effects.
Transplant tolerance is defined as a well-functioning graft
that lacks histological signs of rejection in an immunocom-
petent host in the absence of any immunosuppressive drugs
(150).
‘‘Operational transplant tolerance’’ is a clinical situation
defined as stable graft function without clinical features of
chronic rejection and in the absence of any immunosup-
pressive drugs, usually for longer than 1 year (151).
However, current tests and biomarkers cannot indicate
tolerance to the graft. Validated indicators or biomarkers of
immunologic tolerance and biomarkers able to predict and
diagnose graft dysfunction, acute and chronic rejection, and
the level of immunosuppression potentially allow for
individualized therapy and the safe minimization or with-
drawal of immunosuppressive therapy in certain transplant
recipients (150).
Experimental models of the immune system’s response to
transplantation have identified two key events that lead to
tolerance in the recipient: the deletion of a considerable
fraction of alloreactive T-cells and the development of T-
regulatory cells that protect the graft from being attacked by
the immune system (150). Some evidence indicates that the
terminal pathway in destroying the transplanted organ, as
occurs in acute rejection, is the same pathway that destroys
tissues in many other inflammatory processes, such as
immune-mediated tumor rejection, autoimmune disease,
cardiovascular events, chronic obstructive pulmonary dis-
ease, and infection clearance. This common pathway has
been called the ‘‘immunologic constant of rejection’’ (152).
Microarrays that quickly analyze thousands of genes have
been used to study the mechanisms and pathways of acute
rejection in organ transplantation. In an interesting meta-
analysis, Spivey et al. reviewed the literature for all the most
common pathways of acute allograft rejection in humans,
as determined by microarray technology. The pathways
reported in the immunologic constant of rejection hypoth-
esis are the same pathways as those occurring in acute
allograft rejection. Microarray analysis may help to deter-
mine the mechanism that controls the balance between
tolerance and rejection (153). Because of the large number of
genes that can be analyzed, the microarray technique can be
used to study the mechanism of activation of the immuno-
system directly in the human body, bypassing experiments
in animal models.
Currently, new techniques that can rapidly measure and
analyze large amounts of different biological substances and
that will help identify new biomarkers include the following:
1) Genetic analysis with real-time PCR, microarrays, and
genome-wide association.
2) Flow cytometry and Luminex-based techniques for
measuring large numbers of cells and their products.
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3) Mass spectrometry for measuring and identifying
proteins.
Genetic Analysis
Real-time PCR can test a small number of genes with high
sensitivity and specificity. Microarrays can quickly analyze
thousands of genes and determine whether they are
activated or suppressed. Microarray analysis is more cost-
effective then real-time PCR for studying a large number
of genes, but its sensitivity and specificity are lower. Since
2001, microarrays have been used in various solid-organ
transplant studies to identify specific patterns of gene
expression that can predict and characterize acute and
chronic rejection and transplant tolerance (154). Chen et al.
used microarray analysis of the biopsies of transplanted
hearts in acute rejection to identify 45 upregulated genes
that may be correlated with rejection (155).
Genome-wide association studies can be described as
whole-genome scans that can identify single nucleotide
polymorphisms in a small amount of DNA (156). The theory
is that the association between a polymorphism and a
disease phenotype can be used as a genetic marker to aid in
diagnosis and prognosis. Transplant centers in the UK and
Ireland are currently using this type of analysis to identify
genes for kidney transplant failure (157). If this technique is
applied to a cardiac transplantation population, it may also
identify clinically useful biomarkers in that population.
Gene Expression Profiling
Applying genetic testing to cardiac transplantation has
brought about a new, noninvasive test for detecting acute
cellular rejection. Gene expression profiling (GEP) is being
investigated as a potential adjunct to, or even substitute for,
endomyocardial biopsy for monitoring acute cellular rejec-
tion of cardiac allografts in certain clinical situations.
Among the more than 15,000 biomarkers studied so far in
relation to solid-organ transplantation, only 2 are approved
by the FDA and are commercially available: the AlloMapH
and CylexH ImmuKnowTM tests (121).
The AlloMapH test uses quantitative real-time PCR to
measure the expression of 20 genes (11 informative, 9
control and normalization) in peripheral blood mono-
nuclear cells (133,158). The test was developed on the
premise that peripheral blood mononuclear cells may reflect
host responses to the allograft. It has been available for
clinical use through the Clinical Laboratory Improvement
Amendment certified XDx, Inc. reference laboratory since
January 2005 (159).
The AlloMapH test was developed using DNA microarray
technology and validated with quantitative real-time PCR.
The 11 informative genes represent several biologic path-
ways, including T-cell activation (PDCD1), T-cell migration
(ITGA4), mobilization of hematopoietic precursors (WDR40A
and cMIR), and steroid-responsive genes (ILIR2, FLT3, and
ITGAM). The remaining nine AlloMapH genes are controls
for test accuracy and reproducibility (133,158). A score from 0
to 40 is generated using a multigene algorithm. The test was
developed and validated through the Cardiac Allograft
Rejection Gene Expression Observational (CARGO) study,
with the aim to distinguish between a quiescent state (grade
0R by the revised ISHLT grading) and moderate-to-severe
rejection (a grade of 3A/2R or higher by the original
and revised ISHLT grading of rejection, respectively).
Importantly, GEP could detect the absence of moderate-to-
severe rejection and thus identify a state of quiescence, with
score thresholds varying with the time after transplant (.2 to
#6 months, .6 to #12 months, or .12 months).
The test has a high negative predictive value, which
ranges from approximately 98% to 99% for scores consid-
ered to be appropriate thresholds in each of the three time
periods after transplant (133,158,159). One year after
transplantation, scores of less than 34 were associated with
a negative predictive value of more than 99% for grade 3A/
2R rejection, suggesting the clinical utility of this test is
its ability to rule out acute cellular rejection (158,159). The
positive predictive values for GEP of 34 or more were low,
however, with values decreasing from 20% to 40% during
the first 6 months after transplant to approximately 7.8% at 1
year after transplantation. This decline in PPV is thought to
be related to the decrease in the incidence of acute rejection
with time from transplantation (133,158,159). These findings
indicate that GEP has a high sensitivity and low PPV for
detecting acute cellular rejection over time.
AlloMapH scores and the histologic results of cardiac
biopsies sometimes differ. High GEP scores in the setting of
negative biopsy results is the more common phenomenon
and may be caused by early or focal rejection that may be
missed on biopsy as a result of sampling error. Additionally,
immune processes related to conditions other than acute
cellular rejection (e.g., AMR, infection, cardiac allograft
vasculopathy, or chronic rejection) may be associated with
higher AlloMapH scores. AlloMapH scores also tend to
increase with time after transplantation, even with quies-
cence, and values must be interpreted in this context.
Higher GEP scores in the setting of quiescence are thought
to be related to down-titration of corticosteroids and other
immunosuppression. However, the clinical importance of
an AlloMapH score above a threshold in the setting of
quiescence is as yet unknown (133,158,159).
AlloMapH testing is currently being used in clinically
stable cardiac transplant recipients aged 15 years or older at
6 months or more after transplantation to identify those at
low-risk for moderate or severe (Grade $3A/2R) cellular
rejection. The test has also been used as an adjunct to clinical
evaluation and endomyocardial biopsy in monitoring for
rejection and in lieu of biopsy in patients 6 months or more
after transplant who are at low risk of rejection (159,160). Its
application should be individualized and the results
interpreted in the context of the patient’s overall clinical
status and risk of acute rejection. The frequency of
surveillance should be individualized and a thorough
clinical evaluation performed at the time of testing,
including echocardiographic assessment of allograft func-
tion (159). Thresholds should also be individualized and
decisions regarding biopsy or changes in immunosuppres-
sion made according to each patient’s risk for acute
rejection.
AlloMapH is not recommended for use in patients who
are at high risk for acute rejection or graft failure, including
pregnant women, patients who have received blood
transfusions in the prior 30 days, patients who have
received hematopoietic growth factors affecting leukocytes
within the prior 30 days, and patients who have received
high-dose steroids within the past 21 days or who are taking
20 mg/day or more of prednisone equivalent. The test has
not been validated for use in children less than 15 years
of age.
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The AlloMapH test has distinct advantages over biopsy in
that it is a less-invasive method for monitoring acute cellular
rejection in cardiac allograft recipients. Its genetic basis
also has the advantage of having the potential to predict
episodes of acute rejection, which may help to guide risk
stratification, monitoring, and treatment (161,162). The
clinical usefulness also extends to its applicability in
managing immunosuppressive regimes to minimize the
risk and complications of toxicity while also minimizing the
risk of rejection.
The importance of GEP scores in cardiac allograft
vasculopathy and in AMR are also areas of investigation
(163). These studies are, however, limited by small patient
numbers, and their usefulness in children is limited by the
fact that most results are from data in adults. AlloMapH
scores in patients less than age 15 years remain to be
validated.
Adenosine Triphosphate Release as a Measure of
Immune Function
The CylexH ImmuKnowTM cell function assay (CICFA)
has been promoted as a way to monitor the integrity of cell-
mediated immunity. The assay measures the adenosine
triphosphate (ATP) concentrations in CD4+ T-cell lympho-
cytes after stimulation with phytohemagglutinin-L. High
CICFA concentrations correspond with immune compe-
tence and low concentrations with immune suppression
(164). In adult solid-organ transplant patients, low CICFA
concentrations were associated with a risk of infection, and
high CICFA concentrations were associated with a risk of
acute organ rejection (165). In an observational study of 296
heart transplant patients, Kobashigawa et al. found that
patients with assay results below normal were at higher risk
for infectious complication related to elevated immunosup-
pression, but attempts to predict rejection were inconclusive
(166).
There have, however, been conflicting results. A retro-
spective study of 111 adult heart transplant patients found
that CICFA did not predict either infection or rejection (167).
In this study, two patients had three episodes of cellular
rejection, and the CylexH response did not correlate with
these periods of rejection. Few studies have evaluated the
use of CICFA in children. Hooper et al. established the
normal ranges of immune assay concentrations in healthy
children, both those less than and greater than 12 years old,
and in stable renal transplant recipients greater than 12
years old (168). These ranges are the basis for studying
CylexH ImmuKnowTM assays in children. Gautam et al.
used the ImmuKnowTM assay to adjust the dosing of
immunosuppressive medications in a child with lympho-
proliferative disorder after kidney transplantation (169). The
assay can thus be used to predict the degree of immuno-
suppression and to adjust medications in young transplant
recipients.
However, the use of the ImmuKnowTM assay in pediatric
heart transplantation is very limited. We found only one
study that assessed its use in children with heart trans-
plants. The retrospective study by Rossano et al. of 83
children with heart transplants reported 20 episodes of
cellular rejection, but ATP concentrations measured by the
ImmuKnowTM assay did not differ between children with
and without rejection. The authors concluded that CICFA
concentrations did not predict acute rejection or clinically
important infections (170). Thus, given these conflicting
results, larger multicenter studies are needed to determine
whether ATP concentrations can aid in titrating immuno-
suppressive therapy and in reducing adverse effects.
Genome Transplant Dynamic
Because rejection is associated with apoptosis and cell
death and because free DNA is released into plasma, Snyder
et al. used single nucleotide polymorphism (SNP) technol-
ogy to measure the presence of free donor DNA as a percent
of recipient DNA in the plasma of transplant recipients at
the time of endomyocardial biopsy. The correlation between
the percentage of donor DNA and rejection increased with
the severity of the rejection. Furthermore, these investiga-
tors also found that an elevation in donor DNA was
detected even before biopsy-proven rejection and that it
returned to normal after treatment. On the ROC curve, a
threshold of 1.70% donor DNA identified grade 2R rejection
with an 83% true positive rate and a 16% false positive rate
(171). A test that directly measures the extent of cardiac
damage, along with the AlloMapH test, which measures the
signal of the host immune system indicating rejection, may
further increase the sensitivity and specificity of detecting
rejection.
Mass Spectrometry
Mass spectrometry can analyze proteins in different body
fluids and now includes tandem spectrometry to obtain new
protein sequence information (172). Mass spectrometry of
bronchoalveolar lavage fluid has proved useful in diagnos-
ing bronchiolitis obliterans syndrome in lung transplant
recipients with 94% specificity and 74% sensitivity (173).
Flow Cytometry
Flow cytometry and Luminex-based techniques measure
specific cells and their subsets along with the production of
cytokines and other cell functions. These techniques are
useful in transplantation (174). Measuring the concentra-
tions of T- and B-lymphocytes and their subsets can help
determine the level of immunosuppression and the
response to immunosuppressive treatment. The diagnostic
specificity and the amount of antibodies can also be
determined. Limitations include inter-laboratory variability
and the inability to cover all the alleles in the population.
Antibodies against HLA in the transplanted organ are
associated with chronic rejection and a lower rate of organ
survival. In 243 cardiac transplant patients with no DSAs
before transplantation, Smith et al. found that the develop-
ment of DSAs was associated with a marked decrease in
survival (hazard ratio, 4.35), independent of the ability to
fix complement. More patients with DSAs died of CAV or
acute rejection than did patients with non-DSAs. Although
the authors were not able to show a cause–effect relation-
ship between DSAs and CAV, having both DSAs and CAV
was associated with a worse prognosis. The results of this
study also emphasized the importance of regular monitor-
ing for the presence of DSAs, starting in the first year after
transplantation (175).
Antibodies to non-HLA antigens are also associated with
an increased risk of CAV. Kalache et al. reported that the
myosin-specific antibodies and T-cells were independently
associated with the development of CAV (odds ratio, 45;
95% CI, 4 to 500) and can be used as predictors of outcome
in cardiac transplant recipients (176).
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Concentrations of alloreactive T-cells derived from the
memory pool can also be used to predict outcomes in
transplant patients. Ongoing multicenter studies in heart
and kidney transplant recipients are assessing the feasibility
and standardization of measuring memory T-cells to guide
the management of immunosuppressants. However, the
high cost and complexity of this technique are major
obstacles to its widespread implementation (135).
Summary and Future Translational Research
Directions in Heart Transplantation
In this review, we have presented current challenges and
approaches to the care of children who have received a heart
transplant. Specifically, we have reviewed the mechanisms
of cardiac transplant rejection and the roles of endomyo-
cardial biopsy and biomarkers, such as biomarkers of
inflammation, cardiomyocyte injury, or stress, in detecting
cardiac graft rejection. We have also reviewed CAV. Lastly,
we addressed the role of genetic analyses, including
genome-wide association studies, gene expression profiling
using entities like AlloMapH, and adenosine triphosphate
release as a measure of immune function using the CylexH
ImmuKnowTM cell function assay.
Clearly, there has been significant progress in the care of
post-transplant pediatric patients using the approaches
described above. One theme that has emerged is the
importance of further investigations of existing cardiac
biomarkers, whether circulating proteins or genetic biomar-
kers, and identifying novel cardiac biomarkers to better
predict the clinical course after heart transplantation in
children. The goal is to minimize the need for resource-
intense and potentially risky myocardial biopsies and to
better guide therapeutic interventions. Beyond 1 year of life,
most pediatric heart transplants occur in children with
cardiomyopathy. Recent reports show the knowledge gap
regarding cardiac biomarkers in pediatric cardiomyopathy,
heart failure, or congenital cardiovascular malformations,
which results from a lack of large multisite clinical trials
(177). If noninvasive biomarkers could reliably improve
clinical monitoring and prognosis, both before and after
heart transplantation, they could serve as important
surrogate endpoints in both observational studies and
clinical trials. New investigations into mechanistic path-
ways, as identified by existing and novel cardiac biomarkers
and recipient genotypes as biomarkers (including the
expression of genetic polymorphisms), could result in
important advances in the monitoring of these children
and result in improved outcomes for children receiving a
heart transplant (178,179).
While continued translational research regarding
mechanistic and genetic studies in children who have
received a heart transplant is vital to improved patient
outcomes, there is a complementary research approach that
also needs to be vigorously pursued to result in the best
evidence-based approach to the evaluation, monitoring, and
decision making regarding the listing of these children for
heart transplant. Many risk factors and outcome predictors
in children eligible for cardiac transplantation can be
identified early in these children’s clinical course. Since
the mid-1990s, the National Heart, Lung, and Blood
Institute-funded Pediatric Cardiomyopathy Registry
(PCMR) has conducted epidemiological and longitudinal
follow-up studies of thousands of children with cardiomyo-
pathy, which is the most common indication for heart
transplantation after infancy (180,181). During this period,
the PCMR has reported risk factors for either death or
heart transplant using their pre-transplant dataset.
Additionally, the PCMR has combined their data with
the peri- and post-transplant data from the Pediatric Heart
Transplant Study (PHTS) (182-184) to better characterize
the clinical course and risk factors for the outcomes of
these children from cardiomyopathy diagnosis to post-
cardiac transplant follow-up.
With regard to pediatric cardiomyopathy, the PCMR and
the PCMR-PHTS collaborations have identified the follow-
ing predictors of the risk of transplant or death, which have
not previously been reported. These results could result in
better evidence-based decisions regarding listing for heart
transplantation by pediatric cardiologists. In children with
dilated cardiomyopathy, those with a familial or myocardi-
tis etiology had a very good survival experience versus other
etiologies, particularly idiopathic dilated cardiomyo-
pathy (185). In a competing risk analysis of children with
idiopathic dilated cardiomyopathy, age .6 years at diag-
nosis, heart failure, left ventricular dilation, decreased left
ventricular function, and decreased height-for age predicted
worse clinical outcomes (186). However, in this same group,
increased left ventricular dilation was predictive of an
increased risk of transplantation but not death. The
conclusion was that left ventricular dilation may be over
emphasized in listing decisions in idiopathic cardiomyo-
pathy patients by pediatric cardiologists, whereas linear
growth retardation may not be considered in listing
decisions, despite its risk for increased mortality.
In another PCMR study, it was found that children with
myocarditis and impaired ejection function at diagnosis and
children without left ventricular dilation and increased
septal thickness were most likely to experience echocardio-
graphic normalization (187). Although hypertrophic cardi-
omyopathy is not regularly a criterion for cardiac
transplantation listing for children, PCMR results showed
that children with hypertrophic cardiomyopathy who
present at less than 1 year of age have a very poor prognosis
and should be considered for listing for heart transplant
(188). For those children with hypertrophic cardiomyopathy
in the setting of Noonan syndrome who present with heart
failure at less than 6 months of age, the prognosis is even
more dire. Although this group of patients is rarely listed or
transplanted, the PCMR data suggest a more aggressive
clinical approach regarding listing for heart transplant for
these children in the absence of contraindications (189). For
children with cardiomyopathy who have received a heart
transplant, the combined PCMR-PHTS pre- and post-trans-
plant analyses are equally informative. These studies have
determined that a strategy of directing donors preferentially
to the sickest children, as defined by the need for intravenous
inotropic or mechanical support, is appropriate (190). Finally,
PCMR-PHTS analyses determined that children with myo-
carditis who received a heart transplant had significantly
highermortality post-transplantation comparedwith children
with cardiomyopathy from a non-myocarditis etiology (191).
These findings suggest that children with myocarditis listed
for transplant should be maintained medically until acute
inflammation resolves before they undergo heart transplanta-
tion. All these results suggest the importance of robust
longitudinal clinical research studies, in combination with
immunologic, genetic, and circulation biomarker studies, in
the pre- and peri-transplant period to improve the outcomes
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of children with conditions that could be treated with cardiac
transplantation.
& FINAL CONSIDERATIONS
As discussed here in the different sections, there has been
some success in identifying limitations in solid-organ
transplant-related issues. However, the potential to expand
research and to resolve these issues is great. In terms of
AMR, an area requiring further attention is the allograft
injury caused by the binding of C1q to DSAs. Therefore,
therapies that target C1q can help prevent chronic allograft
injury. The recurrence of FSGS can be prevented by
understanding the mechanism of proteinuria and identify-
ing the cPF, which can then be targeted for therapy.
We speculate that a combination of genomics and proteo-
mics will identify a large number of biomarkers and provide
information that may further improve our ability to predict
outcomes in transplantation, thereby facilitating a new branch
of personalized medicine for transplant recipients.
At the bedside, the large amount of data generated by the
techniques listed above should be combined with the
subjective clinical information that is not always suitable
for mathematical analysis. New statistical analyses may
need to be created for accurate evaluation and to facilitate
the transition of information to clinical practice.
Only through a strong interdisciplinary effort, as men-
tioned above, will a translational approach to patient care
advance knowledge in the field of pediatric transplantation.
To this aim, we have described the basis for a strong clinical
research effort in transplantation that will generate new
evidence-based tools. At the same time, we recommend the
implementation of a ‘‘bedside to the bench’’ approach with
the goal of evaluating and caring for each patient with
individualized treatments. This approach will involve the
development and validation of minimally invasive assays
that can predict transplant outcomes and guide therapeutic
decisions in each of these highly vulnerable children.
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